After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?
Hyperimmune Globulin Could Prove Superior
After the FDA's emergency use authorization for convalescent plasma, pushed on by President Trump, an alliance of firms is working with the NIH to conduct a robust study of a potentially more potent alternative.
You may also be interested in...
NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.